|Articles|September 1, 2000

Implementing Optimal Guidelines for Growth Hormone Use in a Managed Care Population
Volume 6
Issue 15 Suppl

Growth Hormone Use in Pediatric Growth Hormone Deficiency and Other Pediatric Growth Disorders

Author(s)Ron Rosenfeld, MD, David B. Allen, MD, Margaret H. MacGillivray, MD

Download PDF: Growth Hormone Use in Pediatric Growth Hormone Deficiency and Other Pediatric Growth Disorders

Articles in this issue

almost 26 years ago

Article

Participating Faculty

almost 26 years ago

Article

Introduction

almost 26 years ago

Article

Clinical and Reimbursement Issues on Growth Hormone Use in Adults

almost 26 years ago

Article

Growth Hormone Use in Transitioning Patients -- Clinician and Payer Concerns

almost 26 years ago

Article

Recommendations on Improving the Use of and Managed Care Review Process of Growth Hormone Therapy

almost 26 years ago

Article

Clinician and Payer Issues in Managing Growth Hormone Deficiency

almost 26 years ago

Article

CME / CPE / CCMCE Quiz

almost 26 years ago

Article

Selected Abstracts

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Growth Hormone Use in Pediatric Growth Hormone Deficiency and Other Pediatric Growth Disorders

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Medicaid MFN Pricing Could Save $8.6 Billion

Active US Drug Shortages Rise for Third Straight Quarter

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD